WHIPPANY, New Jersey, Feb. 27 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news:

* * *

Bayer's XOFIGO(R) (radium-223 dichloride) plus enzalutamide demonstrates significant overall survival benefit in PEACE-3 trial in patients with metastatic castration-resistant prostate cancer with bone metastases

* Final results for the key secondary endpoint of overall survival (OS) . . .

Click here for more information about our products